Artelo biosciences announces successful completion of first cohort in a phase 1 study of art26.12

The first selective fatty acid binding protein 5 inhibitor safely administered to human subjects initial safety and pharmacokinetic data expected during the first half 2025 solana beach, calif., jan. 13, 2025 (globe newswire) -- artelo biosciences, inc (nasdaq: artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, or dermatologic and neurological conditions, today announced the completed safety review of the first cohort of eight healthy volunteers in the company's phase 1 study of art26.12.
ARTL Ratings Summary
ARTL Quant Ranking